The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]

Abstract

Walling DP, Hassman HA, Anta L, et al. Drug Des Devel Ther. 2021;15:4371–4382. Page 4378, Table 2, PK Parameter column, the text “Cave (ng/nL)” should read “Cave (ng/mL)”. Page 4379, Table 3, PK Parameter column, the text “Cave (ng/nL)” should read “Cave (ng/mL)”. The authors apologize for the errors. Read the original article

Keywords

• bioequivalence
• comparative bioavailability
• long-acting injectables
• lais
• pharmacokinetic
• risperidone
• schizophrenia